In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
BeiGene Ltd. (immuno-oncology) netted $875.5mm through its initial public offering on the Main Board of the Stock Exchange of Hong Kong Ltd. (SEHK). The company sold 65.6mm ordinary shares at $13.76 (the mid-point of its $12.03-14.22 range). Of the total, 5.9mm shares were offered to the public in Hong Kong and 59.7mm shares were offered globally. BeiGene completed its US initial public offering on the Nasdaq Global Select Market in February 2016, through which it netted $170mm with the sale of 7.6mm American Depositary Shares (representing 98.7mm ordinary). Current proceeds will go towards development, regulatory activities, and future commercialization of zanubrutinib (mantle cell lymphoma), tislelizumab (classical Hodgkin's lymphoma), and pamiparib (solid tumors including ovarian, gastric, and brain tumors), and will also support pipeline expansion in cancer and possibly other indications.
In Vitro Diagnostics
Drug Discovery Tools
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?